KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities: 2009-2024

Historic Other Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $128.8 million.

  • Biomarin Pharmaceutical's Other Non-Current Liabilities rose 27.87% to $163.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $163.1 million, marking a year-over-year increase of 27.87%. This contributed to the annual value of $128.8 million for FY2024, which is 7.41% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Other Non-Current Liabilities stood at $128.8 million for FY2024, which was up 7.41% from $119.9 million recorded in FY2023.
  • Biomarin Pharmaceutical's 5-year Other Non-Current Liabilities high stood at $128.8 million for FY2024, and its period low was $98.4 million during FY2021.
  • For the 3-year period, Biomarin Pharmaceutical's Other Non-Current Liabilities averaged around $116.3 million, with its median value being $119.9 million (2023).
  • In the last 5 years, Biomarin Pharmaceutical's Other Non-Current Liabilities decreased by 13.86% in 2021 and then grew by 19.92% in 2023.
  • Biomarin Pharmaceutical's Other Non-Current Liabilities (Yearly) stood at $114.2 million in 2020, then dropped by 13.86% to $98.4 million in 2021, then grew by 1.68% to $100.0 million in 2022, then climbed by 19.92% to $119.9 million in 2023, then rose by 7.41% to $128.8 million in 2024.